Incidence, prevalence and risk factors for hepatitis C in Danish prisons

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

  • Jacob Soholm, Univ Southern Denmark, University of Southern Denmark, Inst Clin Res, Res Unit Clin Epidemiol
  • ,
  • Dorte Kinggaard Holm, Odense Univ Hosp, Odense University Hospital, Dept Clin Immunol
  • ,
  • Belinda Mossner, Univ Southern Denmark, University of Southern Denmark, Inst Clin Res, Res Unit Clin Epidemiol
  • ,
  • Lone Wulff Madsen, Univ Southern Denmark, University of Southern Denmark, Inst Clin Res, Res Unit Clin Epidemiol
  • ,
  • Janne Fuglsang Hansen, Odense Univ Hosp, Odense University Hospital, Dept Infect Dis, Univ Southern Denmark, University of Southern Denmark, Inst Clin Res, Res Unit Clin Epidemiol
  • ,
  • Nina Weis, Univ Copenhagen, University of Copenhagen, Dept Vet Clin & Anim Sci, Fac Med & Hlth Sci
  • ,
  • Agnes Pernille Sauer
  • ,
  • Tahany Awad, AbbVie AS, Med Affairs
  • ,
  • Peer Brehm Christensen, Odense Univ Hosp, Odense University Hospital, Dept Infect Dis, Univ Southern Denmark, University of Southern Denmark, Inst Clin Res, Res Unit Clin Epidemiol

Hepatitis C virus (HCV) infection is prevalent among people in prison and prisons could therefore represent a unique opportunity to test risk groups for HCV. The aim of this seroepidemiological study was to determine the incidence and prevalence of HCV infection and the corresponding risk factors in Danish prisons. Participants, recruited from eight Danish prisons, were tested for HCV using dried blood spots and filled out a questionaire with demographic data and risk factors for HCV infection. In total, 76.9% (801/1041) of all eligible prisoners consented to participate. The prevalence of HCV RNA positive prisoners was 4.2% (34/801) and the in-prison incidence rate was 0.7-1.0 per 100PY overall and 18-24/100PY among PWIDs. Infected prisoners were older than the overall population with a mean age of 42 years and only 17.6% (6/34) were younger than 35 years. The prevalence of PWID was 8.5% (68/801) and only 3% (2/68) of PWID were younger than 25 years. Among the PWID, 85.3% (58/68) had ever received opioid substitution therapy (OST) and 47.1% (32/68) were currently receiving OST. Risk factors associated with HCV infection were intravenous drug use, age >= 40 years, and being incarcerated >= 10 years. In conclusion, the prevalence of PWID in Danish prisons is low, possibly reflecting a decrease in injecting among the younger generation. This together with OST coverage could explain the low prevalence of HCV infection. However among PWIDs in prison the incidence remains high, suggesting a need for improved HCV prevention in prison.

OriginalsprogEngelsk
Artikelnummer0220297
TidsskriftPLOS ONE
Vol/bind14
Nummer7
Antal sider14
ISSN1932-6203
DOI
StatusUdgivet - 26 jul. 2019

Se relationer på Aarhus Universitet Citationsformater

ID: 189902809